Noted businessman supports transformational research
When Dallas businessman and philanthropist H. Ross Perot decided to donate $20 million to MD Anderson, he put his money on personalized cancer therapy. There¡¯s no better return on investment, he says.
¡°I¡¯m proud to support transformational research at MD Anderson over the next decade and to play a small role in making personalized cancer therapy a reality,¡± Perot says.
Gift impact will be felt
Perot¡¯s contributions, supporting the Institute for Personalized Cancer Therapy (IPCT) and the Center for Targeted Therapy (CTT), will have a significant impact on cancer care by accelerating efforts to analyze genetic blueprints, pinpoint molecular biomarkers, develop targeted anti-cancer drugs and test new drugs in clinical trials.
The IPCT, for example, will foster discoveries to help physicians determine specific genetic and molecular abnormalities in each patient¡¯s cancer and in turn prescribe appropriate therapy.
The CTT will speed delivery of new improved targeted drug therapies so that patients may benefit more quickly.
¡°Our goal is to make personalized cancer therapy the gold standard in oncology care,¡± says John Mendelsohn, M.D., president of MD Anderson. ¡°We are grateful to Ross Perot for his generous support in these extremely important areas of cancer research.¡±
